Bayer HealthCare, a subsidiary of Bayer AG, is one of the worldÔÇÖs leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. The pharmaceuticals business operates under the name Bayer Schering Pharma and as Bayer HealthCare Pharmaceuticals in the US and Canada. Bayer HealthCareÔÇÖs aim is to discover and manufacture products that will improve human and animal health worldwide. For more information please see www.bayerhealthcare.com
Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas; Diagnostic Imaging, Haematology/Cardiology, Oncology, Primary Care, Specialised Therapeutics and WomenÔÇÖs Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialised markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. For more information please see www.bayerscheringpharma.de
INSIGHT (International Nifedipine GITS Study - Intervention as a Goal in Hypertension Treatment) showed that nifedipine GITS is an effective antihypertensive agent and is associated with a 50% reduction in CV risk. In addition, Evaluation of Nifedipine and Cerivastatin on Recovery of Endothelial Function (ENCORE) showed that nifedipine GITS has beneficial vascular-protective effects, which slowed the progression of atherosclerosis and improved endothelial function. These effects were independent of BP control.
A Coronary disease Trial Investigating Outcome with Nifedipine GITS (ACTION) proves that nifedipine GITS is safe and effective for the long-term treatment of patients with CAD and angina as it prolongs CV event-and procedure-free survival. ACTION also proves that nifedipine GITS has combined effects on BP lowering and vascular protection, which translate into improved clinical outcomes.
The results of the ACTION hypertensive subgroup analysis show that nifedipine GITS provides greater benefits in this patient group - the primary efficacy endpoint was met, with significant reductions in the risk of stroke and heart failure.
Subgroups from within the ACTION study looking at risk management, safety, atrial fibrillation, coronary calcification and heart failure have demonstrated the further benefits of Adalat in patients with coronary heart disease, angina pectoris and hypertension. Together, INSIGHT and ACTION data make nifedipine GITS the most tested CCB with the best evidence, proving its clinical efficacy for all hypertensive patients, even those at high risk.Ôûá